Key points are not available for this paper at this time.
Abstract Introduction Neoadjuvant chemotherapy (NACT) has emerged as a well-established treatment modality for advanced-stage patients with high-grade serous carcinoma (HGSC). However, relapse and platinum resistance remain significant challenges, resulting in unfavorable long-term outcomes. The interplay between NACT and the tumor microenvironment (TME) is crucial for treatment response, yet its mechanisms are poorly understood. Methods We prospectively recruited 300 newly-diagnosed patients to the Oncosys-OVA study. We performed BRCA1/2 mutational profiling and genomic scarring (ovaHRDscar) to annotate the HGSCs to distinct genomic groups. Detailed surgical and clinical data were collected to assess NACT responses, while histological examination using H 2023 Oct 5-7; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84 (5 Suppl₂): Abstract nr B060.
Junquera et al. (Mon,) studied this question.